Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
Lynn Dorothy Poulton, Macquarie Park (AU); Adam Clarke, Five Dock (AU); Andrew James Pow, Pascoe Vale (AU); Debra Tamvakis, Camberwell (AU); George Kopsidas, Preston (AU); Anthony Gerard Doyle, Drummoyne (AU); Philip Anthony Jennings, Warrawee (AU); and Matthew Pollard, Dural (AU)
Assigned to Cephalon LLC, West Chester, PA (US)
Filed by TEVA PHARMACEUTICALS AUSTRALIA PTY LTD, Macquarie Park (AU)
Filed on Apr. 20, 2023, as Appl. No. 18/304,136.
Application 17/031,615 is a division of application No. 15/206,493, filed on Jul. 11, 2016, granted, now 10,822,422, issued on Nov. 3, 2020.
Application 18/304,136 is a continuation of application No. 17/031,615, filed on Sep. 24, 2020, abandoned.
Application 15/206,493 is a continuation of application No. 14/228,367, filed on Mar. 28, 2014, abandoned.
Application 14/228,367 is a continuation of application No. PCT/AU2012/001161, filed on Sep. 28, 2012.
Claims priority of provisional application 61/541,590, filed on Sep. 30, 2011.
Claims priority of application No. 2011904042 (AU), filed on Sep. 30, 2011.
1. A method for treating a disease or disorder selected from inflammatory bowel disease or irritable bowel syndrome, comprising administering to a subject in need thereof a recombinant antibody that binds to TNF-like ligand 1A (TL1A), wherein the antibody comprises a heavy chain variable region CDR1 comprising amino acids 31 to 35 of SEQ ID NO: 186, a heavy chain variable region CDR2 comprising amino acids 50 to 66 of SEQ ID NO: 186, a heavy chain variable region CDR3 comprising amino acids 99 to 108 of SEQ ID NO: 186, a light chain variable region CDR1 comprising amino acids 23 to 36 of SEQ ID NO: 199, a light chain variable region CDR2 comprising amino acids 52 to 58 of SEQ ID NO: 199, and a light chain variable region CDR3 comprising amino acids 91 to 100 of SEQ ID NO: 199.
